Environmental Health Public

Updated on October **, ****

LILI LIANG

PHONE 347-***-**** EMAIL ****.*****@*****.****.***

SUMMARY

I bring over 12 years of experience in clinical medicine, pharmaceutical industry, and academic research, with a focus on environmental health and public health outcomes. My expertise spans real-world evidence generation, occupational exposure research, and cancer prevention, particularly in underserved communities. During my MPH program, I analyze the neurocognitive impacts of environmental pollutants and contribute to cancer prevention efforts in Chinese American populations.

SKILL SET

Statistical Analysis Skills: Proficient in R and SAS programming languages, familiar with Python Writing Skills: study protocol, conference poster, manuscript, scientific slides deck Research Skills: experiences in real-world study, clinical trial, pharmacoeconomic study Management skills: project management, team management CITI Certificated: GCP for Clinical Trials, CRC Advanced, Data Security and HIPAA training WORK EXPERIENCE

Icahn School of Medicine at Mount Sinai Teaching Assistant for Introduction to Biostatistics (2024 to present)

• Regularly meet with students individually or in groups to practice SAS programming.

• Assist students in interpreting SAS output results and writing code.

• Manage course communications via email and provide additional office hours to review assignments, offer feedback, assist with course concepts, and conduct pre-exam reviews. Icahn School of Medicine at Mount Sinai Research Assistant (2024 to present)

• Conducted qualitative research through focus groups and individual interviews, including coding transcripts and analyzing data, to study cancer screening obstacles among Chinese immigrant women.

• Supported study recruitment and outreach at health fairs, provided trilingual support, and emphasized cancer prevention while engaging community stakeholders and members.

• Utilize R and SAS for data analysis to investigate the effects of occupational exposure on cognitive function. Updated on October 20, 2024

Guangdong Provincial Medical Products Administration Seconded Research Fellow (2022-2023)

• Supported the regulatory and administrative processes for the expedited introduction of imported drugs in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA).

• Responsibilities included assisting in the evaluation of comprehensive drug registration dossiers submitted by multinational pharmaceutical companies, coordinating expert panels to review the clinical efficacy and safety of new pharmaceuticals, and collaborating with the regional Adverse Drug Reaction Monitoring Center to track and analyze global pharmacovigilance data.

Jinan University Research Fellow (HEOR) (2022-2023)

• Led outcomes research operations, overseeing study design, protocol development, and report generation to ensure alignment with regulatory standards and scientific integrity.

• Supervised a team of graduate students in analyzing the adverse effects of three specific drugs, in collaboration with the Guangdong Center for Adverse Drug Reaction Monitoring, and provided actionable insights for updating drug labeling.

• Played a key role in four comprehensive clinical evaluation studies, leading the assessment of clinical efficacy and safety. Responsibilities included designing evaluation frameworks, conducting data analysis, and preparing detailed reports for regulatory submissions and therapeutic recommendations. Chia Tai Tianqing Pharmaceutical Co. Group Medical Manager (Oncology RWE) (2021-2022)

• Responsible for real-world studies operation and evidence generation, focusing on lung cancer, gastrointestinal cancer, and esophageal cancer.

• Led a team of 7 medical managers, overseeing above 20 real-world studies across mainland China.

• Assisted oncologists in the publication of 10+ manuscripts in journals and 9 posters/abstracts at global conferences.

Pierre-Fabre (China) Médicament Co. MSL Manager (Oncology) (2008-2021)

• In charge of oncology medical affairs in pan-Pearl River region.

• Responsible for a phase I study of pipeline drugs in lung cancer(2018-2020). Updated on October 20, 2024

Sanofi-Aventis (China) Pharma Co. Senior MSL (CNS) (2015-2018)

• Won the China General Manager Bravo Award for the 2017-2018 cycle.

• Led a 3M project from 2017 to 2018, project got nominated in 2018 Sanofi global Innovation Awards (iAwards).

• Developed a medical strategy of a antipsychotic drug and implemented in mainland China through the collaborative efforts of a task force the Medical, Marketing, and Market Access (3M) teams. Mundipharma (China) Pharma Co. Medical Science Liaison (2013-2015) Nanfang Hospital Resident (2011-2013)

• Finished residency training in Anesthesiology Department.

• Funded by Nanfang Hospital Dean’s Fund (2012C027) for perioperative research.

• Invited by Guangdong Provincial Anesthesiology Association to give a presentation on its 2011 Annual Symposium. EDUCATION

Icahn School of Medicine at Mount Sinai, MPH candidate, Outcome Research Track cGPA: 3.84 (2023-2025) Massachusetts Institute of Technology MBA (Joint Program) (2015-2018) Sun Yat-sen University MBA (2015-2018)

Southern Medical University MS of Medicine Graduation with Distinction (2008-2011) Guangzhou University of Chinese Medicine Bachelor of Medicine. (2003-2008) PUBLICATIONS

Abstracts

• (Accepted) “The Associations Between Melanoma Mortality and Common Population-Level Exposures to Air Pollution in the US in 2020: An Ecological Study.” Be presented at the 2024 APHA Annual Meeting, Minneapolis, MN. Oct 27-30, 2024.

• (Under Review) “Occupational Exposure to Exhaust Fumes and Cognitive Function in Older Adults in the United States: Results from the National Health and Nutrition Examination Survey.” Submitted to the 2025 American Occupational Health Conference.

• (Under Review) “Beliefs and Barriers to Breast and Colorectal Cancer Screening in Chinese Immigrant Women: A Qualitative Study.” Submitted to the 2025 American Society of Preventive Oncology Annual Meeting. Updated on October 20, 2024

Chapter Book Project

“Review on the role of DREAM in the regulation of pain signals and the preparation of RNA interference vectors.” Advances in Anesthesia. p264-p273. 1st Author. ISBN: 978-7-117-11325-0 (People’s Medical Publishing House, 2009).

Papers

“Determination of Sufentanil in Human Plasma by UPLC-MS/MS.” Anesthesia and Monitoring Forum, 2012,19(5). 1st Author.

“Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target- controlled infusion system.” J Pharm Biomed Anal. 54 (2011) 838-844. 1st Author.

“Research progress on the role of antagonistic regulators of downstream regulatory elements in the regulation of pain signals.” International Journal of Anesthesiology and Resuscitation, 2010,31(2):153-155. 1st Author.

(Natural Science Fund of Guangdong 2008-83025)

“Pharmacodynamic interaction between sevoflurane and sufentanil during induction of anesthesia by response surface method.” China Journal of New Drugs, 2010, 19 (22): 2070-75. Co-Author. SELECTED GRANTS and AWARDS

China General Manager Bravo Award, Sanofi-Aventis Pharma Limited, 2018

Youth Fund of Dean’s Funding (2012C027), Nanfang Hospital, 2012 - 2013

Graduation with Distinction, Southern Medical University, 2011

Graduate Fellowship, Southern Medical University, 2008 – 2011 LANGUAGE SKILLS

English (Fluent), Mandarin (Native), Cantonese (Native) LinkedIn Link

https://www.linkedin.com/in/lili-liang-md-mba-b54b5969/

Contact this candidate